US Physical Therapy
USPH
82.96
-0.67
-0.80%
US Physical Therapy
US · USPH
#3098 by market cap
Listed 1970
82.96
-0.67
-0.80%
Live - 5344 symbols - heartbeat 355s ago
· 2026-10-08 04:36
Pre-market
82.14
-0.99%
After-hours
82.96
0.00%
- Market cap
- 1.24B
- P/E (TTM)i
- 488.00
- P/Bi
- 2.76
- EPSi
- 1.42
- Div yieldi
- 2.19%
- 52W posi
- 76%
Reader sentiment
Are you bullish or bearish on USPH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.85, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +16.33% YoY
Margins
- Gross margin
- 19.17%
- Operating margin
- 10.30%
- Net margin
- 2.76%
Key ratios & quality
- Enterprise valuei
- 1.41B
- Altman Z-Scorei
- 2.85
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 453.91M | 481.97M | 422.97M | 495.02M | 553.14M | 604.80M | 671.35M | 780.99M |
| Gross profit | 101.66M | 112.47M | 94.45M | 117.18M | 112.02M | 121.51M | 123.92M | 149.69M |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 60.31M | 67.43M | 65.91M | 75.25M | 65.91M | 70.02M | 65.63M | 80.43M |
| Pretax profit | 60.21M | 70.91M | 65.51M | 73.20M | 55.57M | 49.38M | 60.21M | 77.81M |
| Tax | 11.37M | 13.65M | 13.02M | 15.27M | 12.16M | 12.16M | 14.61M | 19.81M |
| Net profit | 48.84M | 57.26M | 52.49M | 57.92M | 43.41M | 37.22M | 45.60M | 58.01M |
| Basic EPS | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 1 |
| Diluted EPS | 1.31 | 2.45 | 2.48 | 2.41 | 2.25 | 1.28 | 1.84 | 1.42 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 183.79M | 197.34M | 197.13M | 202.73M | 198.29M | 214.06M |
| Gross profit | 31.07M | 41.62M | 36.87M | 40.13M | 32.75M | 41.94M |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 14.82M | 24.15M | 19.46M | 22.01M | 14.48M | 22.94M |
| Pretax profit | 17.33M | 22.65M | 22.88M | 14.96M | 10.56M | 19.05M |
| Tax | 3.86M | 4.93M | 5.23M | 5.78M | 2.41M | 4.16M |
| Net profit | 13.47M | 17.72M | 17.64M | 9.18M | 8.16M | 14.90M |
| Basic EPS | 1 | 1 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.80 | 0.58 | 0.48 | -0.44 | -0.12 | 0.25 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 79.21M | 85.39M | 87.64M | 95.17M | 111.27M | 233.38M | 137.58M | 139.99M |
| Cash & ST investments | 23.37M | 23.55M | 32.92M | 28.57M | 31.59M | 152.83M | 41.36M | 35.57M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 443.17M | 560.85M | 594.36M | 749.43M | 858.15M | 997.24M | 1.17B | 1.20B |
| Total current liabilities | 41.95M | 60.56M | 93.49M | 83.48M | 85.49M | 102.19M | 116.28M | 139.04M |
| Short-term debt | 1.43M | 27.21M | 32.41M | 31.31M | 41.57M | 42.94M | 50.83M | 52.00M |
| Long-term debt | 38.40M | 50.36M | 16.60M | 117.59M | 175.83M | 138.99M | 142.53M | 152.59M |
| Total liabilities | 92,348,000.00 | 181,394,000.00 | 184,391,000.00 | 296,983,000.00 | 373,586,000.00 | 345,000,000.00 | 408,421,000.00 | 433,811,000.00 |
| Total equity | 350.82M | 379.45M | 409.97M | 452.44M | 484.57M | 652.24M | 759.05M | 770.20M |
| Retained earnings | 167.40M | 184.35M | 212.02M | 224.40M | 232.95M | 223.77M | 227.27M | 227.22M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 145.35M | 140.53M | 138.44M | 139.99M | 139.11M | 139.68M |
| Cash & ST investments | 39.18M | 34.09M | 31.10M | 35.57M | 28.44M | 24.89M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.18B | 1.18B | 1.20B | 1.20B | 1.24B | 1.25B |
| Total current liabilities | 123.80M | 118.84M | 115.08M | 139.04M | 117.30M | 109.91M |
| Short-term debt | 49.38M | 49.21M | 50.76M | 52.00M | 53.58M | 47.43M |
| Long-term debt | 157.24M | 151.91M | 151.46M | 152.59M | 194.04M | 215.46M |
| Total liabilities | 420,679,000.00 | 414,008,000.00 | 413,827,000.00 | 433,811,000.00 | 459,186,000.00 | 482,216,000.00 |
| Total equity | 759.01M | 765.59M | 782.44M | 770.20M | 782.87M | 766.66M |
| Retained earnings | 234.16M | 236.36M | 237.27M | 227.22M | 216.88M | 213.36M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 73.01M | 62.45M | 100.00M | 76.41M | 58.54M | 81.98M | 74.94M | 75.06M |
| Depreciation & amortization | 9.76M | 10.10M | 10.53M | 11.59M | 14.74M | 15.70M | 18.68M | 22.39M |
| Free cash flow | 65.81M | 52.26M | 92.36M | 68.21M | 50.29M | 72.68M | 65.75M | 60.99M |
| Dividends paid | -11.66M | -14.56M | -4.11M | -18.77M | -21.32M | -24.13M | -26.54M | -27.36M |
| Stock buybacks / issuance | -- | -- | -- | 0 | 0 | 163.65M | 0 | -5.57M |
| Ending cash balance | 23.37M | 23.55M | 32.92M | 28.57M | 31.59M | 152.83M | 41.36M | 35.57M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -4.68M | 34.86M | 19.94M | 24.93M | 3.81M | 34.37M |
| Depreciation & amortization | 5.87M | 6.06M | 5.83M | 4.64M | 6.00M | 5.94M |
| Free cash flow | -7.25M | 31.61M | 15.63M | 21.01M | -1.57M | 29.01M |
| Dividends paid | -- | -- | -6.84M | -6.84M | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 39.18M | 34.09M | 31.10M | 35.57M | 28.44M | 24.89M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 7.89 | 13.71 | 12.31 | 10.89 | 9.57 | 4.58 | 5.75 | 4.47 |
| ROA %i | 3.85 | 6.23 | 5.50 | 4.64 | 3.64 | 1.96 | 2.56 | 1.82 |
| ROIC %i | 6.98 | 10.34 | 8.59 | 7.00 | 5.81 | 3.27 | 4.02 | 3.62 |
| 5-year avg ROE %i | 11.51 | 11.47 | 11.33 | 11.22 | 10.87 | 10.21 | 8.62 | 7.05 |
| EBIT margin %i | 13.71 | 15.14 | 15.88 | 14.98 | 11.09 | 9.70 | 10.16 | 11.17 |
| FCF / sales %i | 14.50 | 10.84 | 21.84 | 13.78 | 9.09 | 12.02 | 9.79 | 7.81 |
| Current ratioi | 1.89 | 1.41 | 0.94 | 1.14 | 1.30 | 2.28 | 1.18 | 1.01 |
| Quick ratioi | 1.78 | 1.31 | 0.90 | 1.09 | 1.17 | 2.18 | 1.09 | 0.89 |
| Debt / assetsi | 8.99 | 24.58 | 18.67 | 29.77 | 34.42 | 25.93 | 25.29 | 26.18 |
| LT debt / equityi | 17.78 | 46.04 | 28.45 | 64.87 | 80.36 | 45.28 | 49.99 | 55.24 |
| Interest coveragei | 30.49 | 35.11 | 41.09 | 78.70 | 10.62 | 6.31 | 8.51 | 9.23 |
| Revenue CAGR (3Y) %i | 11.07 | 10.57 | 0.71 | 2.93 | 4.70 | 12.66 | 10.69 | 12.19 |
| Net income CAGR (3Y) %i | -21.16 | 11.05 | 11.49 | 40.16 | 0.14 | -21.70 | -1.66 | -18.93 |
| FCF CAGR (3Y) %i | 28.17 | 6.89 | 23.17 | 1.20 | -1.27 | -7.67 | -1.21 | 6.64 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 6.72 | 7.02 | 7.30 | 4.47 | 1.59 | 0.56 |
| ROA %i | 2.99 | 3.14 | 3.24 | 1.82 | 0.63 | 0.22 |
| ROIC %i | 4.84 | 5.19 | 5.51 | 3.62 | 1.83 | 1.29 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 10.17 | 10.88 | 11.91 | 11.17 | 10.18 | 9.63 |
| FCF / sales %i | 7.99 | 8.34 | 7.50 | 7.81 | 8.38 | 7.89 |
| Current ratioi | 1.17 | 1.18 | 1.20 | 1.01 | 1.19 | 1.27 |
| Quick ratioi | 1.05 | 1.07 | 1.06 | 0.89 | 1.07 | 1.12 |
| Debt / assetsi | 26.05 | 25.89 | 25.78 | 26.18 | 29.21 | 30.89 |
| LT debt / equityi | 51.87 | 51.16 | 51.16 | 55.24 | 65.94 | 75.42 |
| Interest coveragei | 8.54 | 9.06 | 9.86 | 9.23 | 8.13 | 7.27 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Physical therapy operations is the largest reported line at 85.19% of revenue, across 2 reported segments.
- The next-largest line, Industrial injury prevention services, is a distant second at 14.81% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Physical therapy operations85.19%
Industrial injury prevention services14.81%
Quote time 2026-10-08 04:36:53 · For reference only, not investment advice and not tailored to your situation.